deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT02767921

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers

Sponsor: National Cancer Institute (NCI)

Conditions Infiltrating Bladder Urothelial Carcinoma Recurrent Bladder Carcinoma Stage I Prostate Cancer Stage I Renal Cell Cancer Stage II Bladder Urothelial Carcinoma Stage II Renal Cell Cancer Stage IIA Prostate Cancer Stage IIB Prostate Cancer Stage III Prostate Cancer Stage III Renal Cell Cancer
Interventions Cytology Specimen Collection Procedure Laboratory Biomarker Analysis Radical Cystectomy Recombinant EphB4-HSA Fusion Protein Therapeutic Conventional Surgery
Updated 11 times since 2017 Last updated: Nov 15, 2021 Started: Aug 2, 2016 Primary completion: Jan 28, 2020 Completion: Nov 15, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Insufficient accrual

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

A PHASE1 clinical study on Infiltrating Bladder Urothelial Carcinoma and Recurrent Bladder Carcinoma, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 11 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotNot Yet Recruiting~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshotNot Yet Recruiting~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotRecruiting~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshotRecruiting~Jul 2018 – ~Jul 2019 · 12 months · monthly snapshotRecruiting~Jul 2019 – ~Jan 2021 · 18 months · monthly snapshotRecruiting~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshotRecruiting~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshotUnknown Status~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 20 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Unknown Status → Terminated

  4. Oct 2021 — Dec 2021 [monthly]

    Unknown Status PHASE1

    Status: Recruiting → Unknown Status

  5. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

▶ Show 6 earlier versions

  1. Jul 2019 — Jan 2021 [monthly]

    Recruiting PHASE1

  2. Jul 2018 — Jul 2019 [monthly]

    Recruiting PHASE1

  3. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  4. Jul 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting · Phase: NA → PHASE1

  5. Feb 2017 — Jul 2017 [monthly]

    Not Yet Recruiting NA

  6. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting NA

    First recorded

Aug 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • University of Southern California
Data source: University of Southern California

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations